Jennifer R. Brown
Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.
Overview
Jennifer Brown was principal investigator of ALPINE, which showed zanubrutinib improves progression-free survival and causes fewer cardiac events than ibrutinib in relapsed CLL, and led early work on idelalisib and the genetics of familial CLL. She directs the CLL centre at Dana-Farber and leads trials of non-covalent BTK inhibitors and BTK degraders for resistant disease.
Pages like this
not linked directly; found by shared links- PersonJennifer A. Woyach
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
- PersonConstantine S. Tam
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
- PersonJohn C. Byrd
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
- PersonPeter Hillmen
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
- PersonWilliam G. Wierda
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
- PairingCaution: ibrutinib in patients with cardiac risk
Shares ALPINE, Chronic lymphocytic leukaemia.
- ProductPirtobrutinib
Shares BRUIN CLL-321, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
- PersonWilliam D. Tap
Shares Small-molecule kinase inhibitors and the tag trialist.